Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohinoor Dasgupta

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Neural Computation|April 9, 2014
Discovering functional neuronal connectivity from serial patterns in spike train dataCasey Diekman, Kohinoor Dasgupta, Vijay Nair, et al.
Accident; Analysis and Prevention|February 14, 2012
Explaining state-to-state differences in seat belt use: A multivariate analysis of cultural variablesLisa J Molnar, David W Eby, Kohinoor Dasgupta, et al.
British Journal of Clinical Pharmacology|December 31, 2024
Population modelling of nilotinib exposure vs. longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease modelSherwin K B Sy, Deok Yong Yoon, Christelle Darstein, et al.
Clinical Pharmacokinetics|September 7, 2024
Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I MutationFrancois Pierre Combes, Sherwin K B Sy, Ying Fei Li, et al.
Cancer Chemotherapy and Pharmacology|February 28, 2025
Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemiaChristelle Darstein, Deokyong Yoon, Yiqun Yang, et al.
Journal of the National Cancer Institute. Monographs|January 8, 2014
A randomized trial of an avatar-hosted multiple behavior change intervention for young adult smokersLawrence C An, Michele R S Demers, Matthias A Kirch, et al.
Clinical Pharmacokinetics|February 11, 2026
Leveraging Model-Informed Drug Development to Predict Asciminib Efficacy in Second-Line Treatment of Chronic Myeloid Leukemia in Chronic PhaseSherwin K B Sy, Deok Yong Yoon, Yiqun Yang, et al.
Cancer Chemotherapy and Pharmacology|August 23, 2025
Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phaseSherwin K B Sy, Yiqun Yang, Christelle Darstein, et al.
Leukemia Research|September 22, 2019
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemiaDaniel J DeAngelo, Alison R Walker, Richard F Schlenk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2019
Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa StudyDarren R Hargrave, Eric Bouffet, Uri Tabori, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Neural Computation|April 9, 2014
Discovering functional neuronal connectivity from serial patterns in spike train dataCasey Diekman, Kohinoor Dasgupta, Vijay Nair, et al.
Accident; Analysis and Prevention|February 14, 2012
Explaining state-to-state differences in seat belt use: A multivariate analysis of cultural variablesLisa J Molnar, David W Eby, Kohinoor Dasgupta, et al.
British Journal of Clinical Pharmacology|December 31, 2024
Population modelling of nilotinib exposure vs. longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease modelSherwin K B Sy, Deok Yong Yoon, Christelle Darstein, et al.
Clinical Pharmacokinetics|September 7, 2024
Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I MutationFrancois Pierre Combes, Sherwin K B Sy, Ying Fei Li, et al.
Cancer Chemotherapy and Pharmacology|February 28, 2025
Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemiaChristelle Darstein, Deokyong Yoon, Yiqun Yang, et al.
Journal of the National Cancer Institute. Monographs|January 8, 2014
A randomized trial of an avatar-hosted multiple behavior change intervention for young adult smokersLawrence C An, Michele R S Demers, Matthias A Kirch, et al.
Clinical Pharmacokinetics|February 11, 2026
Leveraging Model-Informed Drug Development to Predict Asciminib Efficacy in Second-Line Treatment of Chronic Myeloid Leukemia in Chronic PhaseSherwin K B Sy, Deok Yong Yoon, Yiqun Yang, et al.
Cancer Chemotherapy and Pharmacology|August 23, 2025
Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phaseSherwin K B Sy, Yiqun Yang, Christelle Darstein, et al.
Leukemia Research|September 22, 2019
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemiaDaniel J DeAngelo, Alison R Walker, Richard F Schlenk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2019
Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa StudyDarren R Hargrave, Eric Bouffet, Uri Tabori, et al.
Pageof 2